HealthTree Resources

Watch or read the sources below in order to learn more about bispecific antibody therapy. 

HealthTree News Articles 

2024

• Conferences News Category
• Risk of Infections Using Bispecific Antibodies in Multiple Myeloma 
• BCMA-Directed Therapies in Relapsed Multiple Myeloma
• First R/R Myeloma Patient Treated with New BCMA-Directed Bispecific Antibody in Phase 3 Study
• The Use of Bispecifics and CAR-T in Myeloma Treatment
• New Bispecific Myeloma Treatment to be Reviewed by FDA
• Risk of Infections Using Bispecific Antibodies in Multiple Myeloma

2023

• Effective Management of Bispecific Antibody Side Effects in Myeloma 
• All About IVIG (Intravenous Immunoglobulin)
• Preventing and Managing Immunotherapy Infections in Myeloma 
• Talquetamab Approved for Myeloma Patients by FDA 
• All About TECVAYLI (Teclistamab) 
• The Ground-Breaking Combination of Two Bi-specific Antibody Therapies 
• Sequencing BCMA Therapies with Dr. Joshua Richter 
• A New Bi-Specific Therapy Combination for Relapsed or Refractory Myeloma Patients 
• Wearable Tech for Early Detection of CRS 

2022

• First Bispecific Antibody, Teclistamab, Now FDA Approved in Multiple Myeloma

HealthTree University Videos

• Understanding Immunotherapy
• Know Your Myeloma Therapy 
• All about IVIG (Intravenous Immunoglobulin)
• Conferences Update Section

HealthTree Podcasts, Roundtables and Webinars 

• GPRC5D and FcRH5 Targeted Therapies in Myeloma (2023)
• Know Your Myeloma Immunotherapy: Teclistamab and other Bispecifics (2023)
• Sequencing BCMA Myeloma Therapies (2023)
• The Approval of Teclistamab in Multiple Myeloma with Alfred Garfall, MD, UPENN (2022)

HealthTree Connect Group 

• HealthTree Bispecific Antibody Connect Group

HealthTree Myeloma Acronyms Page

• Acronyms frequently used in multiple myeloma